Oppenheimer updates 2012-2015 EPS Estimates on Alexion Pharmaceuticals (ALXN)

Article Stock Quotes (1) Comments (0)

Following strong first quarter results driven by sales of Soliris, Oppenheimer analysts are updating their EPS estimates on Alexion Pharmaceuticals (NASDAQ: ALXN) for 2012 through 2015. The new estimates are $1.79, $2.43, $3.18 and $4.04, respectively, compared to prior estimates of $1.72, $2.38, $3.03 and $3.87.

“Soliris PNH sales remain on an upward trajectory,” says one Oppenhimer analyst. “We believe ex-US expansion and increasing PNH diagnosis will further drive Soliris sales growth. Notably, we see additional upside in PNH, as ALXN reports the disease remains underdiagnosed. Based on this, we view PNH sales as a continuing Soliris growth driver in '12 and into 1H13.”

Oppenheimer analysts have a $100 price target on ALXN and an OUTPERFORM rating.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $88.90 yesterday, with a 52 week range of $43.78-$101.96.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
• Wedbush Downgrades salesforce.com (CRM) to Neutral

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?